0.45
-0.0031(-0.68%)
Currency In USD
| Previous Close | 0.46 |
| Open | 0.46 |
| Day High | 0.46 |
| Day Low | 0.45 |
| 52-Week High | 1.37 |
| 52-Week Low | 0.43 |
| Volume | 780,993 |
| Average Volume | 1.3M |
| Market Cap | 186.55M |
| PE | -4.54 |
| EPS | -0.1 |
| Moving Average 50 Days | 0.53 |
| Moving Average 200 Days | 0.7 |
| Change | -0 |
If you invested $1000 in Amarin Corporation plc (AMRN) 10 years ago, it would be worth $453.6 as of December 26, 2024 at a share price of $0.454. Whereas If you bought $1000 worth of Amarin Corporation plc (AMRN) shares 5 years ago, it would be worth $20.88 as of December 26, 2024 at a share price of $0.454.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Amarin Receives National Reimbursement for VAZKEPA® in Italy
GlobeNewswire Inc.
Dec 16, 2024 12:00 PM GMT
-- Italian Health Authorities Approve VAZKEPA® (icosapent ethyl) for National Reimbursement to Reduce Cardiovascular Risk in Eligible High-Risk Patients1 -- -- Italy is the Third EU5 Market to Grant National Reimbursement; Ninth National Reimbursemen
Amarin Appoints Peter Fishman Chief Financial Officer
GlobeNewswire Inc.
Dec 13, 2024 2:00 PM GMT
Fishman Previously Served as Global Controller and Principal Financial & Accounting Officer for the CompanyDUBLIN and BRIDGEWATER, N.J., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Peter Fishman has b
Investigators to Present New REDUCE-IT Subanalysis of VASCEPA®/VAZKEPA® (icosapent ethyl) in Patients With and Without Coronary Artery Disease History and Mechanistic Data on Eicosapentaenoic Acid (EPA) at the American Heart Association’s (AHA) Annual Scientific Sessions
GlobeNewswire Inc.
Nov 11, 2024 1:00 PM GMT
DUBLIN and BRIDGEWATER, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that investigators will present an additional subgroup analysis from the landmark REDUCE-IT outcomes trial in patients with and wit